Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Peripheral blood CD4posCD25posFoxP3pos cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig

Fig. 1

AC Clinical outcome of CTLA4-Ig treatment in RA patients. A DAS value across 12 months of follow-up of CTLA4-Ig treatment in RA patients (whole cohort, cohort 1, and cohort 2, respectively); p values were calculated using Wilcoxon matched-pairs signed rank test comparing DAS at pre-treatment and after 3, 6, and 12 months of CTLA4-Ig administration in RA patients (whole RA cohort, RA cohort 1, or RA cohort 2). B CDAI value across 12 months of follow-up of CTLA4-Ig treatment in RA patients (whole cohort, cohort 1, and cohort 2, respectively); p values were calculated using Wilcoxon matched-pairs signed rank test comparing CDAI at pre-treatment and after 3, 6, and 12 months of CTLA4-Ig administration in RA patients (whole RA cohort, RA cohort 1, or RA cohort 2). C Kaplan–Meier survival curve of treatment with CTLA4-Ig across 12 months of follow-up in RA patients (whole cohort, cohort 1, and cohort 2, respectively) for DAS (log-rank test: chi-square = 0.029 p = 0.863; Breslow test: chi-square = 0.346 p = 0.841) and CDAI (log-rank test: chi-square = 0.217 p = 0.641; Breslow test: chi-square = 0.823 p = 0.663). DAS, Disease Activity Score; CDAI, Composite Disease Activity Index; RA, rheumatoid arthritis

Back to article page